Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content
Cancer PHGKB

Specific PHGKB|Cancer|Public Health Genomics and Precision Health Knowledge Base (PHGKB)
Last Posted: Jun 20, 2024
spot light Spotlight

Family communication of cancer genetic test results in an ethnically diverse population: a qualitative exploration of more than 200 patients
(Posted Jun 06, 2024 2PM)

From the abstract: " Previous research on family communication of cancer genetic test results has primarily focused on non-Hispanic White patients with high-risk pathogenic variants (PV). There are limited data on patient communication of moderate-risk PVs, variants of uncertain significance (VUS), and negative results. This qualitative study examined communication of positive, negative, and VUS hereditary cancer multi-gene panel (MGP) results in an ethnically and socioeconomically diverse population. "

Helicobacter pylori Treatment and Gastric Cancer Risk Among Individuals With High Genetic Risk for Gastric Cancer
(Posted May 30, 2024 0PM)

From the abstract: "Question: Is genetic susceptibility for gastric cancer associated with the outcomes of its primary prevention strategies? Findings: In this cohort study of more than 100?000 Chinese adults, a polygenic risk score associated with the risk of gastric cancer was derived. Helicobacter pylori treatment was associated with reduced gastric cancer risk for individuals with a high genetic risk during long-term follow-up but not for those with low genetic risk. Meaning: The findings of this study support the benefits of H pylori treatment for individuals with a high genetic risk of gastric cancer and suggest the utilization of genetic susceptibility for implementing effective gastric cancer primary prevention. "

Harnessing population-wide health data to predict cancer risk
(Posted May 26, 2024 11AM)

From the article: "In an era of big data and efficient computing, the development of complex risk models has become substantially easier than assessing whether, how, and in what context they are useful. The 1976 observation by George E P Box that “All models are wrong but some are useful remains equally true nearly 50 years later. Only time will tell whether the impressive advances since Box's observation in our ability to build risk models will ultimately prove useful for cancer prevention. "

The acceptability and clinical impact of using polygenic scores for risk-estimation of common cancers in primary care: a systematic review
(Posted May 24, 2024 9AM)

From the abstract: "A total of 190 papers were identified, 18 of which were eligible for inclusion. A cancer risk-assessment tool incorporating PGS was acceptable to the general practice population and their healthcare providers but major challenges to implementation were identified, including lack of evidence for PGS in non-European ancestry and a need for healthcare provider education in genomic medicine. A PGS cancer risk-assessment had relatively limited impact on psychosocial outcomes and health behaviours. However, for prostate cancer, potential applications for its use in primary care were shown. "

news Latest News and Publications
5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC. External Web Site Icon
Vamsidhar Velcheti et al. Clin Lung Cancer 2024
A Prospective Questionnaire-Based Study Evaluating Genetic Literacy and Impact of Brief Educational Intervention Among Breast Cancer Patients in a Low- to Middle-Income Country. External Web Site Icon
Ashutosh Mishra et al. Ann Surg Oncol 2024
Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer. External Web Site Icon
Ranjit Manchanda et al. J Natl Compr Canc Netw 2024 22(2D)
Decision aids for female BRCA mutation carriers: a scoping review. External Web Site Icon
Sarah A McGarrigle et al. BMJ Open 2024 14(6) e076876
Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. External Web Site Icon
Michael S Leapman et al. JAMA Netw Open 2024 7(6) e2417274
Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multi-Site Single-Institution Prospective Study. External Web Site Icon
Mouneeb M Choudry et al. J Urol 2024 101097JU0000000000004089
Opportunities for Improving Detection of Cancer Predisposition Syndromes in Pediatric Solid Tumor Patients. External Web Site Icon
Benjamin Hu et al. J Pediatr Hematol Oncol 2024
The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer. External Web Site Icon
Christian Jackisch et al. Breast Cancer Res Treat 2024
Awareness and intention-to-use of digital health applications, artificial intelligence and blockchain technology in breast cancer care. External Web Site Icon
Sebastian Griewing et al. Front Med (Lausanne) 2024 111380940
Digital pathology, deep learning, and cancer: a narrative review. External Web Site Icon
Darnell K Adrian Williams et al. Transl Cancer Res 2024 13(5) 2544-2560


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.